Blog
RSS FeedPosted by Michael Wonder on 30 Jul 2016
A pill too hard to swallow: how the NHS is limiting access to high priced drugs
27 July 2016 - A joint investigation by The BMJ and Cambridge and Bath universities uncovers how NHS England tried to ...
Posted by Michael Wonder on 30 Jul 2016
High cost of new drugs
27 July 2016 - Why government must negotiate a better deal for publicly funded research. ...
Posted by Michael Wonder on 30 Jul 2016
Hollow victories and hepatitis C
28 July 2016 - When Gilead Sciences introduced sofosbuvir based antivirals in 2014, the drugs were touted as a breakthrough for ...
Posted by Michael Wonder on 30 Jul 2016
Cancer sufferers may lose access to effective drugs, says support group
29 July 2016 - Medicine regulator NICE will act as gatekeeper for new treatments, leading to fears NHS patients may be ...
Posted by Michael Wonder on 30 Jul 2016
New drugs available after Cancer Drugs Fund revamp
30 July 2016 - The NHS has announced new potentially life-saving medicines that will be made available to patients as part ...
Posted by Michael Wonder on 30 Jul 2016
Controversial CDF revamp launches
29 July 2016 - England's Cancer Drugs Fund reopens under its new model today, but the pharma industry and charities are ...
Posted by Michael Wonder on 28 Jul 2016
Betting on hepatitis C: how financial speculation in drug development influences access to medicines
27 July 2016 - Victor Roy and Lawrence King argue that the acquisition strategies of drug companies magnify development costs and ...
Posted by Michael Wonder on 28 Jul 2016
NHS 'abandoning' thousands by rationing hepatitis C drugs
28 July 2016 - Addaction says NHS England decision to treat just 10,000 people a year with costly drugs is ‘potential ...
Posted by Michael Wonder on 27 Jul 2016
Vertex seeks deal after NICE rejects CF drug Orkambi
27 July 2016 - NICE has rejected Vertex’s cystic fibrosis drug, Orkambi (lumacaftor+ivacaftor) for routine funding on the National Health Service ...
Posted by Michael Wonder on 27 Jul 2016
Shire and BMS secure NICE recommendations for oncology drugs
27 July 2016 - NICE has issued final guidance recommending Shire’s Oncaspar (pegaspargase) and Bristol-Myers Squibb’s Opdivo (nivolumab) plus Yervoy (ipilimumab) ...
Posted by Michael Wonder on 27 Jul 2016
NICE publishes final guidance on the use of nivolumab in combination with ipilimumab for treating advanced melanoma
27 July 2016 - NICE publishes further guidance on the use of nivolumab (Opdivo) in patients wth melanoma. ...
Posted by Michael Wonder on 26 Jul 2016
Are you paying the NHS for more drugs than you need? Billions worth of life-saving cancer remedies are poured down the drain every year
26 July 2016 - Out of the £5,000 her family paid for medication, a fifth went down the drain. ...
Posted by Michael Wonder on 25 Jul 2016
NICE approves Servier’s Lonsurf as third-line cancer therapy
25 July 2016 - The National Institute for Health and Care Excellence has recommended trifluridine/tipiracil as an option for treating metastatic ...
Posted by Michael Wonder on 24 Jul 2016
Cancer experts write to government to demand life saving drug be used on NHS
24 July 2016 - Cancer specialists from around the UK have written to the Government’s health watchdog to demand a potentially ...
Posted by Michael Wonder on 20 Jul 2016
Breakthrough lung cancer drug must be available on NHS, AstraZeneca says
20 July 2016 - A breakthrough lung cancer drug developed by UK scientists, which passed final clinical trials this week, might ...